Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 2411-2420 Newer>

Pharmaceutical Executive October 1, 2005 Phil Patrick	Marketing to Professionals: Senior-Care Specialists Surge In light of the growing senior population, pharmaceutical marketers are building partnerships with senior specialists.
Pharmaceutical Executive October 1, 2005 Jeffrey Tangney	Alternative Media: Mobile Marketing Through PDAs, pharmaceutical marketers have found an efficient way to communicate with and educate physicians.
Pharmaceutical Executive October 1, 2005	Public Relations: Communications Delivery Chain An interview with Nanccy Turett, president of Edelman Health on how, to regain consumers' trust, pharma must better communicate its mission, goals, and policies.
Pharmaceutical Executive October 1, 2005 Jan Fitzpatrick	Public Relations: Desperately Seeking Value Regulatory angst cools growth in budgets for continuing medical education (CME). The future challenge for CME will be to find that common ground where the interests of academic medicine, medical societies, and practicing physicians intersect.
Pharmaceutical Executive October 1, 2005 Philip A. George	Backpage: Under Surveillance Doctors and consumers don't doubt that pharma benefits society. But in the eyes of the public, industry efforts to monitor postmarket safety come up short.
Pharmaceutical Executive October 1, 2005 Jill Wechsler	Washington Report: Antivirals: Meeting a World of Need The international fight against AIDS requires drugs -- and policy.
Pharmaceutical Executive October 1, 2005	Thought Leader: Room for Improvement An interview with Randal J. Kirk, founder of New River Pharmaceuticals, whose drug technology team has made it its goal to introduce safer, more efficacious and reliable models of existing franchise drugs.
Pharmaceutical Executive October 1, 2005 Patrick Clinton	From the Editor: No Substitutes Don't use surrogate measures in clinical drug trials, says a major industry critic. OK, but don't the critics base a lot of their points on surrogate measures, too?
The Motley Fool October 12, 2005 Stephen D. Simpson	American Healthways Looks Well A keen focus on reducing health-care costs and improving outcomes bodes well for this company's future. This may be a high-growth stock, but it is richly valued at 30 times forward earnings.
The Motley Fool October 11, 2005 Stephen D. Simpson	Genentech Generates Profits Whether you call it a biotech or a pharmaceutical, there's no disputing that Genentech is raking in some big bucks. Trying to value this stock is no treat, but growth-oriented investors should still have much to look forward to over the years.
<Older 2411-2420 Newer> Return to current articles.